Live Breaking News & Updates on Regulatory Outlook|Page 8

Stay updated with breaking news from Regulatory outlook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alberta releases drought response plan

Alberta’s government is releasing its 2024 Drought Response Plan to help support Albertans through any drought conditions this year. ....

South Saskatchewan River , Canada General , Emergency Coordination Centre , Alberta Energy Regulator , Alberta Municipal Affairs , Flood Protection Program , Agriculture Financial Services Corporation , Response Plan , Drought Response Plan , Drought Response , Water Act , Provincial Emergency Coordination Centre , Protected Areas , Alberta Environment , Alberta Agriculture , Alberta Forestry , News Release , Nvironment And Protected Areas , May 2024 , Alberta 39 S ,

SINGAPORE  Southeast Asia's largest lender by assets, DBS Group Holdings, is fighting to demonstrate the results of its digital banking reform ....

Piyush Gupta , Group Holdings , Southeast Asia , Singapore S ,

Insight Global to pay $2.7 million in whistleblower lawsuit

Insight Global LLC to pay $2.7 million to settle allegations in whistleblower lawsuit over covid-19 cybersecurity measures, the Department of Justice announced. ....

United States , Terralyn Williams Seilkop , Us Department Of Justice , Insight Global , Pennsylvania Department Of Health , Department Of Justice , Daily Newsview All , Pennsylvania Department , False Claims Act ,

FDA wary of impact of retirements on inspectional activities

The U.S. FDA’s senior managers often lament the lack of routine increases in taxpayer funding, a concern that Michael Rogers, the associate FDA commissioner for regulatory affairs, reiterated during a May 1 webinar. Rogers said the agency’s field inspectorate will be working through a large number of retirements over the next few years, a predicament he said will continue to be “a huge challenge” to overcome. ....

Michael Rogers , Bioworld Medtech , Fda Office Of Regulatory Affairs , Fda Ora , Fda Oii , Alliance Fora Stronger Fda ,

Since WHIM? Finally, targeted drug enters space from X4

X4 Pharmaceuticals Inc. is raring to go with marketing after the firm scored U.S. FDA approval of Xolremdi (mavorixafor) capsules for patients 12 years and older with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM syndrome, to increase the number of circulating mature neutrophils and lymphocytes. ....

Pharmaceuticals Inc , X4 Pharmaceuticals Inc , Whim Syndrome , Nfections And Myelokathexis ,